Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Robin Garner is an analyst at Craig-Hallum. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/01/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 08/28/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $5.06 | -11.07% | Robin Garner26% | → $4.5 | Initiates | → Buy | Get Alert |
| 04/28/2022 | XERS | Buy Now | Xeris Biopharma Holdings | $5.06 | 28.46% | Robin Garner26% | → $6.5 | Initiates | → Buy | Get Alert |
| 03/18/2022 | CUE | Buy Now | Cue Biopharma | $0.80 | 3150% | Robin Garner26% | $28 → $26 | Maintains | Buy | Get Alert |
| 10/20/2021 | LABP | Buy Now | Landos Biopharma | — | — | Robin Garner26% | → $450 | Initiates | → Buy | Get Alert |
| 08/24/2021 | TRIL | Buy Now | Trillium Therapeutics | — | — | Robin Garner26% | $21 → $18.5 | Downgrade | Buy → Hold | Get Alert |
| 08/02/2021 | FMTX | Buy Now | Forma Therapeutics Hldgs | — | — | Robin Garner26% | → $58 | Initiates | → Buy | Get Alert |
| 04/21/2021 | FENC | Buy Now | Fennec Pharmaceuticals | $6.09 | 179.15% | Robin Garner26% | → $17 | Initiates | → Buy | Get Alert |
| 08/17/2020 | TRIL | Buy Now | Trillium Therapeutics | — | — | Robin Garner26% | → $15 | Initiates | → Buy | Get Alert |
